Literature DB >> 22016475

Impact of multigene assays in early stage breast cancer.

Shelly S Lo1, Kathy S Albain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22016475      PMCID： PMC3233280          DOI： 10.1634/theoncologist.2011-0325

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  12 in total

1.  The oncotype DX recurrence score is correlated with a composite index including routinely reported pathobiologic features.

Authors:  Joseph Geradts; Sarah M Bean; Rex C Bentley; William T Barry
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

2.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

Authors:  Soonmyung Paik; Gong Tang; Steven Shak; Chungyeul Kim; Joffre Baker; Wanseop Kim; Maureen Cronin; Frederick L Baehner; Drew Watson; John Bryant; Joseph P Costantino; Charles E Geyer; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-23       Impact factor: 44.544

3.  The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists.

Authors:  Jennifer E Joh; Nicole N Esposito; John V Kiluk; Christine Laronga; M Catherine Lee; Loretta Loftus; Hatem Soliman; Judy C Boughey; Carol Reynolds; Thomas J Lawton; Peter I Acs; Lucio Gordan; Geza Acs
Journal:  Oncologist       Date:  2011-10-20

4.  Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

Authors:  Gong Tang; Steven Shak; Soonmyung Paik; Stewart J Anderson; Joseph P Costantino; Charles E Geyer; Eleftherios P Mamounas; D Lawrence Wickerham; Norman Wolmark
Journal:  Breast Cancer Res Treat       Date:  2011-01-11       Impact factor: 4.872

5.  Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.

Authors:  J Albanell; A González; M Ruiz-Borrego; E Alba; J A García-Saenz; J M Corominas; O Burgues; V Furio; A Rojo; J Palacios; B Bermejo; M Martínez-García; M L Limon; A S Muñoz; M Martín; I Tusquets; F Rojo; R Colomer; I Faull; A Lluch
Journal:  Ann Oncol       Date:  2011-06-06       Impact factor: 32.976

6.  Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.

Authors:  Gary H Lyman; Leon E Cosler; Nicole M Kuderer; John Hornberger
Journal:  Cancer       Date:  2007-03-15       Impact factor: 6.860

7.  Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Authors:  Kathy S Albain; William E Barlow; Steven Shak; Gabriel N Hortobagyi; Robert B Livingston; I-Tien Yeh; Peter Ravdin; Roberto Bugarini; Frederick L Baehner; Nancy E Davidson; George W Sledge; Eric P Winer; Clifford Hudis; James N Ingle; Edith A Perez; Kathleen I Pritchard; Lois Shepherd; Julie R Gralow; Carl Yoshizawa; D Craig Allred; C Kent Osborne; Daniel F Hayes
Journal:  Lancet Oncol       Date:  2009-12-10       Impact factor: 41.316

8.  Histopathologic variables predict Oncotype DX recurrence score.

Authors:  Melina B Flanagan; David J Dabbs; Adam M Brufsky; Sushil Beriwal; Rohit Bhargava
Journal:  Mod Pathol       Date:  2008-10       Impact factor: 7.842

9.  Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

Authors:  Shelly S Lo; Patricia B Mumby; John Norton; Karen Rychlik; Jeffrey Smerage; Joseph Kash; Helen K Chew; Ellen R Gaynor; Daniel F Hayes; Andrew Epstein; Kathy S Albain
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Authors:  A Goldhirsch; W C Wood; A S Coates; R D Gelber; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2011-06-27       Impact factor: 32.976
View more
  1 in total

1.  Breast cancer genomics: challenges in interpretation and application.

Authors:  Cathy M Kelly; W Fraser Symmans; Eleni Andreopoulou; Giampaolo Bianchini
Journal:  Oncologist       Date:  2013
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.